Pathogenic role of suPAR in FSGS References Nonpathogenic role of suPAR in FSGS References In vitro study suPAR activated β 3 integrin in a similar manner to membrane-bound uPAR in podocytes [9 ] Not repeated by others Podocyte β 3 integrin activation by suPAR was blocked by a blocking antibody specific to uPAR [9 ] Activated podocyte β 3 integrin by plasma from patients with recurrent FSGS could be also reversed by blocking TNF-α [101 ] In vivo mice study High-dose recombinant mouse suPAR induced podocyte integrin β 3 activation, proteinuria, and foot process effacement in a uPAR-knockout ( ) mice [9 ] Neither single-dose nor prolonged administration of recombinant suPAR induced albuminuria or podocyte foot process effacement despite massive suPAR deposits in the glomeruli in wild-type C57BL/6J and 129S2/SvPas mice [68 ] Proteinuria developed after LPS-induced suPAR production in a hybrid-transplant mice in which a kidney from uPAR-knockout ( ) mice was transplanted in a wild-type mouse [9 ] Coadministration of either monomeric or chimeric suPAR produced no additional effect; LPS-induced podocyte effacement and proteinuria in C57BL/6J mice [68 ] Injection of a suPAR -producing plasmid in their skin led to increased serum suPAR concentrations and FSGS-like lesions with proteinuria in genetically engineered wild-type [9 ] Injection of Fc-chimeric suPAR to wild-type mice or continuous expression of suPAR from the liver in new transgenic mice did not induce proteinuria [23 ] Human study suPAR is increased in FSGS compared to other glomerulopathies and healthy subjects [9 –12 ] suPAR is not increased in FSGS compared to other glomerulopathies [14 –21 ] suPAR is more increased in recurrent FSGS after KT than in nonrecurrent FSGS [9 ] Not studied in other groups Pretransplant serum suPAR predicted recurrence of FSGS after KT [9 , 66 ] Pretransplant serum suPAR did not predict recurrence of FSGS after KT [18 , 69 ] Rather, urine suPAR predicted recurrence of FSGS after KT [22 ] Increasing serum suPAR levels after KT predicted recurrence of FSGS [9 ] Serum suPAR levels did not increase at the time of FSGS recurrence after KT [20 ] Serum suPAR levels decreased after plasmapheresis or at remission of FSGS [9 , 10 , 12 , 65 , 66 ] Serum suPAR levels were similar regardless of FSGS recurrence after KT or between nephrotic state and remission of FSGS [15 , 18 , 70 ]